A prospective observational multicenter study assessing the efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in people living with HIV who are either treatment-naive or switched from any tenofovir disoproxil fumarate-containing regimen
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- 06 Oct 2021 New trial record